Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SAVA 
Cassava Sciences Inc (SAVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SAVA (1-star) is a SELL. SELL since 3 days. Simulated Profits (-6.09%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.65% | Avg. Invested days 29 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.54M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta -2.02 | 52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 |
52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.03% | Return on Equity (TTM) -70.6% |
Valuation
Trailing PE - | Forward PE 151.52 | Enterprise Value -35631025 | Price to Sales(TTM) - |
Enterprise Value -35631025 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.26 | Shares Outstanding 48307900 | Shares Floating 43475174 |
Shares Outstanding 48307900 | Shares Floating 43475174 | ||
Percent Insiders 12.79 | Percent Institutions 33.05 |
Upturn AI SWOT
Cassava Sciences Inc
Company Overview
History and Background
Cassava Sciences, Inc. (formerly Pain Therapeutics) was founded in 1998. Initially focused on pain management, it shifted its focus to Alzheimer's disease. Its history includes controversies surrounding the clinical trial data for its Alzheimer's drug candidate, Simufilam.
Core Business Areas
- Neuroscience: Focuses on developing drugs for neurodegenerative diseases, primarily Alzheimer's disease.
Leadership and Structure
Remi Barbier serves as the President and CEO. The company has a board of directors and a management team responsible for overseeing its operations and strategic direction.
Top Products and Market Share
Key Offerings
- Simufilam: An investigational drug for Alzheimer's disease. It aims to restore the normal shape and function of altered filamin A protein in the brain. Market share data is not currently applicable as it is not FDA approved. Competitors are Eli Lilly (LLY) with Donanemab, Biogen (BIIB) and Eisai (ESAI) with Leqembi, and Roche (RHHBY) with Gantenerumab (investigational). These target amyloid plaques, whereas Simufilam targets altered filamin A.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in the Alzheimer's disease treatment sector, is highly competitive and regulated. The market is driven by the increasing prevalence of Alzheimer's disease and the unmet need for effective treatments.
Positioning
Cassava Sciences is positioned as a company developing a novel approach to treating Alzheimer's disease, distinct from amyloid-targeting therapies. Their competitive advantage, if proven effective, would be the unique mechanism of action targeting altered filamin A.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of USD. Cassava Sciences is positioned to capture a significant portion of this TAM if Simufilam proves to be safe and effective.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for Alzheimer's treatment (if proven)
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a single drug candidate (Simufilam)
- Controversies surrounding clinical trial data
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
Opportunities
- Successful completion of clinical trials and FDA approval
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failure
- Regulatory hurdles
- Competition from other Alzheimer's disease treatments
- Negative publicity and skepticism
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ESAI
- RHHBY
Competitive Landscape
Cassava Sciences' competitive advantage lies in its novel approach. However, it faces significant challenges due to its smaller size, controversial history, and the advanced development stages of competing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to Simufilam progression. Historically, it has been volatile, with spikes and drops based on clinical trial announcements and data releases.
Future Projections: Future growth is highly dependent on the success of Simufilam's clinical trials and regulatory approval. Analyst estimates vary widely due to the high-risk nature of the company.
Recent Initiatives: Recent initiatives include advancing Simufilam through Phase 3 clinical trials and conducting studies on SavaDx, its investigational diagnostic.
Summary
Cassava Sciences is a high-risk, high-reward company focused on a novel Alzheimer's treatment. Its success hinges on the positive outcome of clinical trials for Simufilam. The company faces significant challenges related to its past controversies, small size, and intense competition. Positive clinical trial results could lead to substantial gains, while failure could result in significant losses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Financial news outlets
- Analyst reports
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investing in Cassava Sciences involves significant risks, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cassava Sciences Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2000-07-14 | CEO, President & Director Mr. Richard Jon Barry | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://www.cassavasciences.com |
Full time employees 30 | Website https://www.cassavasciences.com | ||
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.